

1 **Hormone replacement therapy and elevated breast cancer risk: An artifact of growth acceleration?**

2

3 Jutta Engel, Gabriele Schubert-Fritschle, Dieter Hölzel

4

5 Munich Cancer Registry (MCR), Institute for Medical Information Processing, Biometry and
6 Epidemiology (IBE), Ludwig-Maximilians-University (LMU), D-81377 Munich, Germany

7

8

9 Corresponding author:

10 Prof. Dr. Dieter Hölzel

11 Munich Cancer Registry

12 D-81377 München, Germany

13 hoe@ibe.med.uni-muenchen.de

14 Tel: ++49-89-8414875

15

16

17

18 Abbreviations:

19 BC breast cancer

20 ER+/- estrogen positive/negative

21 GD Growth duration of BC

22 GF Growth factor

23 HR Hazard Ratio

24 HT hormone replacement therapy

25 HTD hormone replacement therapy duration

26 WHI-S Women health initiative study

27

28

29 Keywords:

30 breast cancer; hormone replacement therapy; tumor growth; risk factor

31

32

33

34

35 Abstract:

36 Background: Available data on accelerated proliferation and increased breast cancer risk due to
37 hormone replacement therapy (HT) are inconsistent. Data on long-term effects of HT are limited. The
38 interaction between several key factors was examined using a model-based approach.

39
40 Methods: Cohorts of 50 year old women, BCs were randomly generated for 30 years based on the
41 age-specific incidence. A control group received a HT that increased the growth of occult BCs. In a 3rd
42 cohort BCs were additionally induced by HT. This model illustrates the interrelationship of important
43 parameters and allows the simulation and comparison of previously published clinical studies.

44
45 Results: Using plausible parameters for BC growth factor (GF) and HT-related effects it was
46 demonstrated that HT caused accelerated growth of occult BCs with an apparent increase in
47 incidence and shortened time to diagnosis. The Women's Health Initiative (WHI) study was
48 reconstructed assuming a GF of 1.43 induced by HT. The decision of millions of women to
49 discontinue or forego HT based on the published risks of the WHI-study in 2002 could explain the
50 marked jump of 6.7% in incidence within a few months. If additional BCs were induced by HT, then
51 these BCs may become apparent after 10 or more years together with those appearing according to
52 the normal incidence. At this time conclusive data on type, timing, and molecular characteristics of
53 HT induced BCs are not yet available.

54
55 Conclusion: The acceleration in growth of occult BC has been underestimated. Initially HTs can cause
56 an apparent increase in BC incidence thereby explaining the WHI-dependent decrease in 2003. A HT
57 associated BC risk should only be detectable with a delay of ten and more years.

58
59
60
61

62 Introduction

63 Hormone replacement therapy, hereafter referred to as hormone therapy (HT), has been the subject
64 of over 50 years of research and discussions leading to a varying use in clinical practice¹. The reasons
65 for this disparity are reported negative and positive side effects of HTs² such as a higher risk for
66 invasive breast cancer (BC), endometrial cancer, or stroke. On the other hand positive side effects
67 have also been published such as a reduced risk for fractures, diabetes, colon cancer, or heart
68 disease. Cost-benefit analyses are complex due to the dependency on age, the type and duration of
69 HT application. Guidelines generally emphasize the need and the benefit of HTs, but also vary in
70 their restrictiveness. A recently updated meta-analysis^{3,4} continues this HT narrative by which
71 approximately 5% or 1 million BCs have been induced by HT since 1990. This result of the study
72 motivated the analysis herein. The main objective was to assess the association of BC with key
73 factors using models based on studies and populations, compare their results, and discuss the use
74 and suitability of the currently available data.

75

76 Methods

77 The models described below were based on cohorts of 50 years old women. BCs were randomly
78 generated for 30 years according to the age-specific incidence^{5,6}. For a comparison with published
79 clinical trials the respective age distributions and competing mortality according to life expectancy
80 were considered. The second cohort begins with HT application, and expected effects of HTs were
81 modeled according to 4 parameters: duration of BC growth (GD), duration of HT application (HTD),
82 and an accelerated growth (GF) due to HT. In the 3rd cohort a BC risk was also modeled. It was
83 assumed that proliferation and BC risk begins and ends with HT application, as the well-known BC
84 incidence jump in 2003 suggests.

85 The modeling approach based on the association of 15 years of GD, 4 years HTD, a doubled GF, and a
86 BC risk is clarified in figure 1. Herein illustrated are the growth trajectories for BCs, the number of
87 tumor cells (log scale), as well as the age of the occult BCs over time. The logarithm of the tumor cells
88 resulted in a linear trajectory for the assumed exponential BC growth. A second key component was
89 the GF, a linear transformation of the growth induced by HT. The impact of growth acceleration may
90 be subdivided into 6 phases (Figure 1B). Plausible model assumptions were taken from peer-
91 reviewed literature, direct comparisons were taken from the Women's Health Initiative Study (WHI-
92 S)^{7,8}, and the updated meta-analysis.³ The model was constructed and all statistical analysis were
93 done in R Version 3.1.3.⁹

94

95 Results

96 *Plausibility of model assumptions*

97

98 For the model a GD of 15 years for ER+ BCs was assumed. Regarding chemoprevention, a rise in
99 incidence in the following 15 years after the end of prevention was not found.¹⁰⁻¹² This conservative
100 presumption is presented in Figure 2A after a 2-year preventive therapy which successfully
101 eradicated 50% of occult and BCs emerging on HTs. A GD of 15 years resulted in a duration of 166
102 days for the required 33 consecutive BC volume doubling of BCs of 20 mm.¹³ The GD was also
103 estimated based on screening data.¹⁴ The calculated 25%/50%/75% percentile for the time required
104 for a volume doubling in women between 60-69 years old and a tumor diameter of 15 mm was
105 65/143/308 days. Applying this to an increase in diameter from 2.5 mm (pT1a) to 28 mm (pT2) with
106 10.5 volume doublings resulted in 1.9/4.1/8.8 years. Based purely on this calculation and beginning
107 with the first tumor cell, all BCs – not just ER+ – would grow to a diameter of 20 mm after 33 VDs in
108 approximately 5.9/12.9/27.8 years.

109

110 In addition a twofold BC risk was assumed for HT (Figure 2A), which by way of the Gail-Model¹⁵
111 estimated a higher prevalence of common risk factors. This model was used in prevention studies to
112 recruit participants and confirmed its results¹¹. However, the GF in the model varied. In Figure 1 the
113 factor of 2 is easily discernible and plausible following the above described doubling times. This GF

114 was also identified from data on the 2.5-fold accelerated growth of ER- compared to ER+ BCs. In BC
115 20% of MET occur 10 years after the initial diagnosis, and together with the BC GD clarify for a time
116 span of 30 years on the x-axis.¹⁶

117

118 *Simulation results*

119

120 Results based on the parameters GD 15 years, HTD 4 years, and GF 2 are shown in Figure 1A. The
121 trajectories illustrate a growth in diameter starting from BC initiation and the effect of HT. The model
122 was based on the cumulative incidence of a cohort of 100 000 50 years old women (Figure 2A, red
123 curve). Initially 216 BCs (SD 14) were randomly generated per year according to the age-specific SEER
124 incidence, 30 years later the cases numbered 372 (SD 21) (Fig.2B), with an overall total of 10 219 (SD
125 105) BCs without considering competing risks. The slight curvature was a result of the increased
126 incidence due to age, which is why only 40% of BCs occurred within the first 15 years.
127 Chemoprevention applied over two years effective in 50% of cases could have prevented 2 431 or
128 24% BCs.

129

130 The application of HT stimulated the growth of occult BCs (Figure 2A, green curve). This lead to six
131 marked follow-up periods P1-6 (Fig.1B) associated with HTD and GF. Three variations of this
132 stimulated growth can be described, namely with 4 years of HTD with a GF of 2 there is a cumulation
133 of BCs in the first two years, twice as many were diagnosed overall compared to the control group.
134 Period P1 ends after two years (HTD/GF) at a turning point for the cumulative incidence. This point is
135 defined by BCs that became apparent under HT 0 to a maximum of 2 years earlier following a linear
136 course (Figure 1B P1 red with HT).

137

138 The second variation begins after 4 years when all BCs have been exposed throughout the HTD and
139 become symptomatic two years earlier through this induced growth (Figure 1B green, P2-4 with HT).
140 A gap subsequently appears in P4 (Figure 2B). In P4-6 (Figure 1B, brown) BCs were diagnosed also
141 exhibiting accelerated growth that arise according the age-specific incidence for women aged 50
142 years or older under HT. The shift in this third variation spans from 0 to a maximum of two years
143 similar to P1, however in the form of its mirror image. The consequences were as follows: The first
144 BCs are maximally expedited and the duration of diagnosis is expanded thus lowering overall
145 incidence. However, the cohort under HT (Figure 2A green) exhibits the same number, although
146 faster growing, BCs as those without HT. Up until P6 the same number of BCs become evident and
147 thereafter there is no longer a HT effect..

148

149 The concept that HT may induce de novo BCs was also simulated (Figure 1-2, blue). If HT caused BCs
150 and these would be induced during HT with an accelerated growth rate, then these induced BCs
151 would become apparent in the same phase P4-6 as the age-dependent BCs. A twofold BC-risk would
152 double the number of normally HT induced BCs during an exposure to HT for women 54 years old or
153 younger. A second turning point would be expected starting from P4 when the hazard rate would
154 again increase due to BC risk (Figure 2C). It should be noted that HR at the 2nd turning point is likely
155 to underestimate the true BC risk. If the growth of HT-induced BCs is also accelerated, then initiation
156 occurs in P1-2 and diagnosis in the expanded period P4-6 (Fig.1B).

157

158 This type of non-proportional hazard rate can remain latent in an overall analysis. The hazard ratios
159 (red vs. green) were identical up to the turning point due to the linear GF-transformation, only the
160 confidence interval decreases due to the increasing number of patients. The HR is the quotient of the
161 number of BCs that initially became evident with or without HT, therefore HR at this turning point is
162 equivalent to the GF. After the turning point the HR fell to 1 in P6, meaning that even at the end of
163 the HT the HR already underestimated the proliferative effect (HR 1.55 after 4 years in Figure 2A). If a
164 BC risk is present (blue vs. red comparison) the HR may again increase from P4. Post interventional

165 analysis (Figure 2C) can exhibit time lagged effects that may result in a protective effect in
166 comparison to a cohort without HT.¹⁷

167
168 Due to the overlapping influence of BC risk and the proliferative effect small risks hardly become
169 evident in studies with small sample sizes, a follow-up period spanning over 2 decades, and a lack of
170 model assumptions. On the other hand it can be confirmed that the initial increase in incidence can
171 be caused by the accelerated growth of previously existing BCs. Interpreting this as a BC-risk is
172 therefore incorrect, it would be an incidence-increase imitation-bias.

173
174 *The women health initiative studies*

175
176 In order to model the WHI-S the following data are used: Incidence, age-distribution, competing
177 risks, and a sample cohort of 8 506 receiving HT with estrogen plus progestin for a total of 5.6 years.
178 After 7.2 years the HR reached 1.24 (95%CI: 1.05 – 1.43).⁸ This HR can be achieved with a GF of 1.43
179 (95%CI: 1.18 – 1.78) with a turning point after 3.9 (5.6/1.43) years. The effect of the WHI-S can be
180 explained with a boost in growth through HT (Figure 3). If after 13 years (HR=1.3, 95%CI 1.01-1.27)
181 the HR continues to decrease, then there is no BC-risk with HT. Currently published is a HR of 1.29
182 (95%CI 1.14-1.47) based on 16.1 years of follow-up¹⁸. This would correspond to a twofold BC risk
183 after 19 years (HR 1.28, 95%CI 1.16-1.40).

184
185 Even if the long-term results of the WHI-S were modeled with proliferation and BC risk, the
186 discrepancy between the incidence curves should be noted. A negative mammography exam as an
187 inclusion criterion could shift the first date of diagnosis of ER+ BCs by months, however a shift of 3
188 years as shown in the WHI-S is not plausible. This delayed opening of curves could not be reproduced
189 in the WHI observational study which corresponds to Fig.3.¹⁹ A GF of 1.43 offered an explanation for
190 the study results but did not directly explain the immediate drop in incidence observed in the United
191 States after the publication of the study in July 2002. There was a 6.7% or 11.8% drop of BCs in all
192 women or between the ages of 50-69 between 2002 and 2003 and the decrease was more evident in
193 those with ER+ BCs.^{5,20}

194
195 This simultaneous decline in the incidence of BCs and HT prescriptions can most likely be attributed
196 to the publication of the associated BC risk. Simulations and the study data showed that HTs do lead
197 to an apparent short-term increase in the incidence. This increase was just as brief and reversible as
198 the change in breast density that results from HT discontinuation. Figure 1B illustrates the continued
199 forward shift that resulted from a continued HT application. It should also be considered if no HT was
200 started due to published BC risk, then no proliferative effect was induced accordingly. Taken together
201 these results point to one reason for the observed drop in incidence, namely the decision of many
202 women to abstain from or discontinue HT due to a perceived BC risk.

203
204 The simulation showed 8 506 women and 49/36 BCs in the first year with/without HT, in 100 000
205 women this added up to a total of 701/499 BCs. These results fluctuated because of the random
206 generated data. Transferring these findings to the 203 500 newly diagnosed cases of BC in 2002 in
207 the USA²¹, out of which 44% were diagnosed between the age of 50-69, would explain the 11.8%
208 drop in incidence equivalent to 10 570 BCs. A decline of this magnitude can be attributed to a GF of
209 1.43 and an average incidence of 360/10**5 in patients under HT if 6.8 million women discontinued
210 or abstained completely from HT. A simulation of the WHI-S resulted in a difference of approximately
211 200 accelerated BCs out of 10**5 women after HT and 5.3 million women. However, the number of
212 women under HT in total has decreased by 5 million between 2001 to 2003.²²

213
214 *The meta-analysis*

215

216 The updated meta-analysis summarized unique data from 58 clinical studies, included almost 150
217 000 BCs, and follow-up data of up to 20 years.³ Results herein for different HTD and post intervention
218 phases were shown for the HT model with estrogen plus progestin. The remarkably high HRs for
219 current users contradict these modeling results. A nearly implausible GF of 4 would still not be
220 obtainable even after a HTD of 7 years and a resulting HR of nearly 2.

221
222 If the relative risk is determined using case-control studies the inclusion criteria must be observed in
223 order to separate the two effects, growth acceleration and BC induction, according to Fig.2. Up to
224 the turning point of the HT, the relative risk also estimates the GF. With an increasing time since HT
225 in P2-P4, the HRs of past users kept becoming smaller compared to those of current users. If the sum
226 of the HT duration and the time since the end of the HT reaches the mean GD of the BCs in P4-P6 for
227 past users the BC risk can be analyzed. For several of these constellations, an increased BC risk of
228 approximately 1.2 was shown after more than 10 years. An apparent protective effect due to
229 proliferation (Fig. 2C red vs. green) cannot be seen, as in the WHI-S.

230
231 As with the WHI-S attention was also drawn to the increased BC mortality after 20 years for HT user.
232 ²³ The term proliferation was missing, so that an increased incidence did not differentiate between
233 accelerated growth and BC risk.

234

235 Discussion

236

237 The incidence and the associated BCs in the control group without HT are used as model parameters.
238 The GD of ER+ BC varies greatly but 15 years appears to be a plausible assumption based on the
239 exponential growth and volume doublings estimated from screening. The widening gap between
240 incidence- and survival curves of chemoprevention and adjuvant therapy also highlight this
241 observation. A GF of 1.43 explains the results of the WHI-S.^{8,19} The proliferation observed in HT
242 exposed BCs characterised by a short-term increase in breast density and cellular activation is known
243 from imaging during screening. This effect is reversible within a few weeks. Switching growth on and
244 off through HT is the only plausible explanation for the sudden drop in BC incidence in 2002/2003.^{5,24}
245 The change appears to be limited to the luminal A-like BC subtype and can be reversed by HT
246 discontinuation.²⁵ Similarly an increased level of Ki67 indicates an increased proliferation in benign
247 breast tissue samples.²⁶ This specific proliferative activity leads to a more frequent diagnosis of ER+
248 BCs under HT ¹⁹ compared to the ER- BCs 2.5 times faster growth rate.

249

250 While the HTs appear to accelerate short-term growth, the cellular pathways and characteristics of
251 the induced BCs have so far not been adequately described. It is biologically plausible that BCs
252 caused by HT are delayed.²⁷ A risk relative to the age-specific incidence for women during HT was
253 modeled. However, the assumption that the BC risk follows a linear increase and can be switched on
254 and off similar to the proliferation activity is not plausible. Many risks do not follow a linear course,
255 and at this time there is no evidence that HTs enable the rapid formation of the necessary driver
256 mutations. This assumption would be in strong contrast to most other tumor types where
257 carcinogenesis processes develop over years or even decades.^{28,29} By applying sensible assumptions
258 the first BCs induced through HT would manifest at a later time, perhaps even 20 years after the start
259 of HT.

260

261 In addition, data on the difference between BC-associated mutations promoted immediately through
262 HT and those that occur normally as a result of serial mutations according to the known incidence
263 remain to be reported. Are genetic modifiers of HT associated BCs available soon? Are there fewer
264 passenger mutations due to short-term transformations in cancer cells? Do the 4% of occult BCs in 50
265 year old women present with a distinctive signature from the HT promoted growth? Do the BCs have
266 an inherent memory for the exposition to HT? Is the growth boost dependent on tumor size? The
267 molecular processes involved offer a unique research platform to study complex cancer pathways.³⁰

268
269 Even epidemiological data currently do not offer sufficient evidence for HT-induced BC-risk.³¹ The
270 chemoprevention results clarify that short-term eradication of prevalent BCs decreased the BC rate
271 over more than 15 years.¹⁰ Similar results were seen for other risk factors such as alcohol
272 consumption and smoking, which have an effect on cancer incidence after decades. However, up to
273 this point it has not been proven that a withdrawal of HT can stop or even eradicate an already
274 initiated cancerous growth. If the BC risk is efficiently reduced by millions of women who abstain
275 from HT, then this should have a long-term effect on incidence. However, there was only a drop in
276 incidence in 2002/2003 following the initial publication of the WHI-S and so far no further increase in
277 the past 15 years.⁵ I.e. the status quo ante was already an artifact, the incidence has increased with
278 the increasing use of HT, as the SEER data from 1995-2000 show. After the publication of the study
279 results on the secondary prevention of coronary heart disease by HTs³² the BC incidence and the HT
280 use have both continued to decline since 1999.^{33,34}

281 The time with which BCs occur earlier increases continuously and reaches a maximum of HTD/GF
282 years. The incidence in a population increases accordingly. If BCs grow 15 years, no induced BCs are
283 expected in the first 10 years after the start of HT with a GF <1.5.

284
285 There is no valid evidence and it is not plausible²⁷ that occult BCs shortly before becoming manifest
286 should abandon their autonomous growth, regress, or only become evident at a later time through
287 HT discontinuation.^{20,35,36} Even a slowly decreasing participation rate for screening examinations
288 cannot explain this effect.^{34,37} The jump in incidence of about 10 000 BCs is a real effect and was
289 achieved by about 5 million women not beginning or discontinuing an HT. With 360 BCs per 100,000
290 annually, this would achieve a short-term proliferation with a GF 1.59. A BC risk that only slowly
291 increases with the duration of the therapy, as in meta-analysis, would lead to an implausibly high
292 number of women who refrained from HTs or discontinued HTs. Since a GF of a specific HT should be
293 uniform it would be desirable to prepare different HRs for the incidence curves when long-term
294 follow-up is available.

295
296 Even if no evidence is available on a higher risk for recurrent cancer, then the entire process of
297 cancerogenesis should be accelerated under HT. This includes the growth of BCs, tumor cell
298 dissemination, and growth of prevalent metastases. Through this type of proliferation more cases of
299 interval cancers, with a larger tumor size, increased number of node positive lymph nodes, and faster
300 growing metastases occur as shown in the discussed studies.^{8,23,38} The 15-year survival of BCs with a
301 diameter of 17 vs. 15 mm⁸ varies by 3%, a change from 11 to 15mm increases this difference to 5%.³⁹
302 For this reason an annual instead of 2-3 yearly screening would have and will reduce proliferation risk
303 in women with HT. A small increase in mortality is therefore plausible even without the additional BC
304 risk.

305 Modeling the effect of a few parameters on the cumulative incidence and the post-interventional risk
306 is a valuable approach. The interactions are complex, but in the sense of Occam's razor, proliferation
307 is a simple principle that can explain observations and stimulate the generation of hypotheses. For
308 example the effect of a wash-out period of HTs on proliferation would be quite illogical. Rather, the
309 sum of all HT-intervals should be correlated with the incidence. The increase in BC with prior HT use
310 in the WHI-S has now been shown.¹⁸ Modeling studies can aid in continually specifying research
311 objectives, prerequisites for future observations, and data analysis approaches. The previously
312 discussed time-dependency and the P1-6 time-shifted effects are obstacles for any type of case-
313 control studies. The immense value of prospective studies and real world data with follow-up data
314 over decades becomes clear, since there is no valid data to point to specific factors which are
315 correlated with frequency and timing of additional HT-induced BCs. This constitutes a major
316 limitation: data is missing that allows models to be verified and improved.

317
318 The WHI-S showed that millions of women discontinued or completely abstained from HTs due a fear
319 of cancer. By foregoing HTs many women suffering from postmenopausal symptoms have accepted a

320 lower quality of life^{2,40,41}. That should not be repeated. There are no valid estimates which of the 1
321 million BCs simply occurred earlier or which were induced with what timing. Balanced information
322 also about possible induced and delayed BCs for women are necessary even after 50 years of HT.

323

324 **Conclusion**

325

326 HTs appear to boost the growth of occult BCs, leading to an apparent rise in the overall incidence. A
327 GF of 1.43 was estimated for the WHI-S which explains the decrease in incidence in 2002/2003. HT
328 induced BCs would manifest simultaneous to the BCs originating under HT according to the age
329 specific incidence. Although sound data on proliferation is available, type, timing, and especially the
330 molecular characteristics of HT-induced rapidly growing BCs are currently not readily available. This
331 work is mainly based on the analysis of cancer registry data and basic metastasis process. Modeling
332 studies may aid in specifying research objectives and also provide direction during the search for
333 effects in large datasets.

334

335

336 **Key clinical points**

337 **Hormone Therapy for Postmenopausal Women**

338

- 339 • The reported BC risk of HTs reduced their use after the publication of the WHI study in 2002
340 and caused an immediate 6.3% decrease in the incidence in the SEER data
- 341 • To date there is no reliable data on how large the BC risk is according to the type and
342 duration of the HT
- 343 • Hormone receptor positive BCs grow slowly, on average maybe 15 or more years
- 344 • The increase in incidence with the onset of HTs can only be caused by a faster growth of
345 occult hormone receptor positive BCs.
- 346 • Information is lacking on how quickly HTs induce the necessary driver mutations and
347 whether these de novo BCs differ from normal BCs
- 348 • Induced BCs, even if mutations occur in a flash, are only likely to occur with a time delay of
349 10 or more years with growth factors < 1.5
- 350 • The 6.3% jump in incidence in a single year can only be caused by preventing faster growth
- 351 • The increased incidence in the SEER data up to this jump is correlated with the increasing HT
352 use and caused by the assumed faster growth of occult BCs

353

354

355

356 Appendices:

357 Disclosure The authors have declared no conflicts of interest.

358

359

360


361 **Acknowledgment**

362 We thank Doris Mayr, Sylvia Heywang-Köbrunner, Christian Thaler, Michael Lauseker for valuable
363 scientific and technical advice, Ingo Bauernfeind for the Project Group Breast Cancer for the
364 opportunity to present and discuss preliminary results. Kathrin Halfter helped us with the manuscript
365 and in particular, we would like to thank the staff of the Munich Cancer Registry for their meticulous
366 and systematic recording and maintenance of the data.


367

368

369 Fig.1: Tumor growth and the effects of hormone replacement therapy (HT)
 370 A: The x-axis represents age beginning at 50 years with a second x-axis representing the BC growth
 371 time relative to the beginning of the cohort. Double-sided arrows depict the time span of BC growth
 372 (black, mean 15 years) and the HT (4 years, red and gray area). On the left y-axis the number of
 373 tumor cells is shown (log-scale and example tumor diameters in mm), the right y-axis the age of the
 374 occult BCs. Their trajectories follow an exponential growth and are therefore shown as lines. Each
 375 trajectory depicts one of three respective growth spurts caused by HT (HTD of 4 years) with dashed
 376 lines representing the control group. The blue points at the top and bottom symbolize the origin of
 377 additional induced BCs and their shift in time to diagnosis after HT. (Periods: see Fig. 1B and legend).
 378




379
 380 B: Diagnosis of BC with and without HT with a GD of 15 years, HTD 4 years, and a GF 2. The
 381 proliferation caused by HT initiates a transformation of the BC-free time span leading to 6 separate
 382 phases. The resulting concentration of BCs at the beginning leads to an apparently increased
 383 incidence. The 6 vertical lines distinguish time periods during follow-up: 1. HT beginning, 2. Turning
 384 point (HTD/GR), 3. End of HT, 4. Diagnosis of first BCs initiated or induced after start of HT and
 385 accelerated by HT, 5. Mean time of BC growth: Limit for all BCs prevalent at time=0. 6. End of HT
 386 effects (GD+HTD).
 387



388
 389


390 Fig 2: Simulation of the cumulative BC incidence for women starting from 50 years of age using the
391 model parameters GD 15, HTD 4, GF 2, twofold BC risk.
392 A: Cumulative BC incidence according to currently reported incidence (red), with accelerated growth
393 after HT and the same number of BCs (green), and additional BC risk (blue). Were a cohort to receive
394 a 50% effective chemoprevention for two years, the incidence would increase again two years after
395 GD. Overlapping lines were manually shifted for better illustration.
396



397
398

399 B: BC cases per year for each of the three cohorts of Fig. 2A without HT (red), with HT (green), and
400 additional BC risk of HT (blue). The effect of GF 2 (green) with the concentration of cases in P1
401 (incidence doubling), the expedition of BCs, and the expansion in P4-5 are clearly evident for the
402 same number of BCs. The HT induced BCs all occur during P4-5 (blue). Yearly fluctuations are caused
403 by random generation. Overlapping lines were manually shifted to improve visualization.


404



405


406

407 Fig.2C Cumulative incidence starting 4 years after HT end (post-HT cumulative incidence)
408



409

410 **Fig.3** Simulations of the WHI-S using a cohort of n=8 506 according to their respective age-
411 distribution (Mean age 63.7) and competing risks. HTD 5.6 years and GF 1.43 result in a HR of 1.26
412 after 7.2 years as reported in the WHI-S.
413



414
415

416 References

- 417
- 418
- 419 1. Lobo RA. Hormone-replacement therapy: current thinking. *Nature reviews Endocrinology*
- 420 2017;13:220-31.
- 421 2. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for
- 422 perimenopausal and postmenopausal women. *The Cochrane database of systematic reviews*
- 423 2017;1:Cd004143.
- 424 3. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal
- 425 hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide
- 426 epidemiological evidence. *Lancet* 2019;394:1159-68.
- 427 4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone
- 428 replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705
- 429 women with breast cancer and 108,411 women without breast cancer. *Collaborative Group on*
- 430 *Hormonal Factors in Breast Cancer. Lancet* 1997;350:1047-59.
- 431 5. Noone A, Howlander N, Krapcho M, Miller D, Brest Ae. SEER Cancer Statistics Review, 1975-
- 432 2015 National Cancer Institute. Bethesda, MD.; <http://seer.cancer.gov/> (accessed March 20, 2020).
- 433 6. Munich Cancer Registry. [http://www.tumorregister-](http://www.tumorregister-muenchen.de/en/facts/specific_analysis.php)
- 434 [muenchen.de/en/facts/specific_analysis.php](http://www.tumorregister-muenchen.de/en/facts/specific_analysis.php) (accessed March 20, 2020).
- 435 7. Writing Group for WHI Investigators. Risks and benefits of estrogen plus progestin in healthy
- 436 postmenopausal women: principal results From the Women's Health Initiative randomized controlled
- 437 trial. *Jama* 2002;288:321-33.
- 438 8. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast
- 439 cancer and mammography in healthy postmenopausal women: the Women's Health Initiative
- 440 Randomized Trial. *Jama* 2003;289:3243-53.
- 441 9. R Core Team. R: A language and environment for statistical computing. R: Foundation for
- 442 Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>. 2015.
- 443 10. Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II):
- 444 long-term results of a randomised controlled trial. *Lancet* 2019.
- 445 11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer:
- 446 current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *Journal of the*
- 447 *National Cancer Institute* 2005;97:1652-62.
- 448 12. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer
- 449 risk reduction: American Society of Clinical Oncology clinical practice guideline. *Journal of clinical*
- 450 *oncology : official journal of the American Society of Clinical Oncology* 2013;31:2942-62.
- 451 13. Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: role in
- 452 interpretation of studies of prevention and menopausal hormone therapy. *Cancer epidemiology,*
- 453 *biomarkers & prevention : a publication of the American Association for Cancer Research,*
- 454 *cosponsored by the American Society of Preventive Oncology* 2012;21:1038-48.
- 455 14. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor growth
- 456 estimated through mammography screening data. *Breast cancer research : BCR* 2008;10:R41.
- 457 15. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing
- 458 breast cancer for white females who are being examined annually. *Journal of the National Cancer*
- 459 *Institute* 1989;81:1879-86.
- 460 16. Hölzel D, Eckel R, Bauerfeind I, et al. Improved systemic treatment for early breast cancer
- 461 improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year
- 462 results from the Munich Cancer Registry. *Journal of cancer research and clinical oncology*
- 463 2017;143:1701-12.
- 464 17. Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus
- 465 Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized
- 466 Clinical Trials. *JAMA oncology* 2015;1:296-305.

- 467 18. Chlebowski RT, Anderson G, Aragaki A. Long-term influence of estrogen plus progestin and
468 estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials
469 SABCS Abstract 2019;GS5-00.
- 470 19. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer
471 incidence and mortality in the Women's Health Initiative Observational Study. *Journal of the National*
472 *Cancer Institute* 2013;105:526-35.
- 473 20. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in
474 the United States. *The New England journal of medicine* 2007;356:1670-4.
- 475 21. Jemal A, Thomas A, Murray T, Thun M. *Cancer statistics, 2002*. CA: a cancer journal for
476 clinicians 2002;52:23-47.
- 477 22. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy:
478 annual trends and response to recent evidence. *Jama* 2004;291:47-53.
- 479 23. Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer
480 mortality. *Lancet* 2019;394:1139.
- 481 24. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of
482 hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review.
483 *Hum Reprod* 2005;20:2052-60.
- 484 25. Wunderle M, Pretscher J, Brucker SY, et al. Association between breast cancer risk factors
485 and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
486 *Breast cancer research and treatment* 2019;174:453-61.
- 487 26. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement
488 therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased
489 epithelial proliferation in the normal postmenopausal breast. *The Journal of clinical endocrinology*
490 *and metabolism* 1999;84:4559-65.
- 491 27. Shapiro S, Farmer RD, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement
492 therapy cause breast cancer? An application of causal principles to three studies: Part 1. The
493 Collaborative Reanalysis. *The journal of family planning and reproductive health care* 2011;37:103-9.
- 494 28. Gerstung M, Jolly C, Leshchiner I, et al. The evolutionary history of 2,658 cancers. *Nature*
495 2020;578:122-8.
- 496 29. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and
497 colorectal cancers. *Science (New York, NY)* 2006;314:268-74.
- 498 30. Rudolph A, Hein R, Lindstrom S, et al. Genetic modifiers of menopausal hormone
499 replacement therapy and breast cancer risk: a genome-wide interaction study. *Endocrine-related*
500 *cancer* 2013;20:875-87.
- 501 31. Shapiro S, Farmer RD, Stevenson JC, Burger HG, Mueck AO, Gompel A. Does hormone
502 replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies.
503 *The journal of family planning and reproductive health care* 2013;39:80-8.
- 504 32. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary
505 prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin
506 Replacement Study (HERS) Research Group. *Jama* 1998;280:605-13.
- 507 33. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal
508 hormone therapy after the publication of clinical trial results. *Annals of internal medicine*
509 2004;140:184-8.
- 510 34. Sprague BL, Trentham-Dietz A, Remington PL. The contribution of postmenopausal hormone
511 use cessation to the declining incidence of breast cancer. *Cancer causes & control : CCC* 2011;22:125-
512 34.
- 513 35. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin
514 in postmenopausal women. *The New England journal of medicine* 2009;360:573-87.
- 515 36. Narod SA. Hormone replacement therapy and the risk of breast cancer. *Nature reviews*
516 *Clinical oncology* 2011;8:669-76.

- 517 37. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. Declines in invasive breast
518 cancer and use of postmenopausal hormone therapy in a screening mammography population.
519 Journal of the National Cancer Institute 2007;99:1335-9.
- 520 38. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study.
521 Lancet 2003;362:419-27.
- 522 39. Engel J, Weichert W, Jung A, Emeny R, Holzel D. Lymph node infiltration, parallel metastasis
523 and treatment success in breast cancer. Breast (Edinburgh, Scotland) 2019;48:1-6.
- 524 40. Pinkerton JV. Hormone Therapy for Postmenopausal Women. The New England journal of
525 medicine 2020;382:446-55.
- 526 41. Burger HG, MacLennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the
527 impact of the WHI on women's health. Climacteric : the journal of the International Menopause
528 Society 2012;15:281-7.

529